{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:47:49Z","timestamp":1787993269669,"version":"build-2784847793"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Oral daily ibandronate was investigated for the prevention of bone loss in postmenopausal women without osteoporosis (n = 653). BMD at the lumbar spine and hip were significantly increased (3.1% and 1.8%, respectively; p \u2264 0.0001 versus placebo) with 2.5 mg ibandronate after 24 months. Oral ibandronate is a promising option for the prevention of postmenopausal bone loss.<\/jats:p>\n               <jats:p>Introduction: Further strategies to manage patients most at risk from developing postmenopausal osteoporosis are required. The objectives of this multicenter, double-blind, randomized, placebo-controlled study were to examine the efficacy, tolerability, and optimal dose of oral daily ibandronate in the prevention of bone loss in postmenopausal women.<\/jats:p>\n               <jats:p>Materials and Methods: In total, 653 women (mean bone mineral density [BMD] T-score &amp;gt; \u22122.5 at the lumbar spine), who had been postmenopausal for at least 1 year, were allocated to one of four strata based on time since menopause and baseline lumbar spine BMD. Women were randomized to receive calcium (500 mg daily) plus either placebo (n = 162) or ibandronate 0.5 mg (n = 162), 1 mg (n = 166), or 2.5 mg (n = 163) as once-daily oral treatment for 2 years. The primary endpoint was the mean percent change in lumbar spine BMD with ibandronate versus placebo.<\/jats:p>\n               <jats:p>Results and Conclusions: After 2 years, oral daily ibandronate produced a dose-related and sustained maintenance or increase in BMD at the lumbar spine and hip (total hip, femoral neck, trochanter), together with a dose-related reduction in the rate of bone turnover. The greatest nominal increases in spinal and hip BMD were observed with the 2.5-mg dose, which produced statistically significant BMD gains compared with placebo at 6 months and all subsequent time-points at the spine and hip (3.1% and 1.8% increase in lumbar spine and total hip BMD, respectively, versus placebo; p \u2264 0.0001 after 24 months). Oral daily ibandronate was well tolerated with an incidence of upper gastrointestinal adverse events similar to placebo. No safety concerns were identified. In summary, oral daily ibandronate 2.5 mg decreases bone turnover, preserves or increases BMD in the spine and proximal femur, and is well tolerated. Oral ibandronate provides a promising option for the prevention of bone loss in postmenopausal women.<\/jats:p>","DOI":"10.1359\/jbmr.0301202","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T05:58:24Z","timestamp":1146117504000},"page":"11-18","source":"Crossref","is-referenced-by-count":96,"title":["Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without Osteoporosis"],"prefix":"10.1093","volume":"19","author":[{"given":"Michael R","family":"Mcclung","sequence":"first","affiliation":[{"name":"Oregon Osteoporosis Center, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D","family":"Wasnich","sequence":"additional","affiliation":[{"name":"Radiant Research, Honolulu, Hawaii, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Recker","sequence":"additional","affiliation":[{"name":"Osteoporosis Research Center, Creighton University School of Medicine, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A","family":"Cauley","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles H","family":"Chesnut","sequence":"additional","affiliation":[{"name":"Osteoporosis Research Group, University of Washington Medical Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine E","family":"Ensrud","sequence":"additional","affiliation":[{"name":"Department of Medicine, VA Medical Center, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Burdeska","sequence":"additional","affiliation":[{"name":"Pharma Department, F Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Mills","sequence":"additional","affiliation":[{"name":"Pharma Department, F Hoffmann-La Roche Inc., Nutley, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024013019221788700_bib1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF01623782","article-title":"Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease","volume":"7","author":"Kanis","year":"1997","journal-title":"Osteoporos Int"},{"key":"2024013019221788700_bib2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jbmr.5650070902","article-title":"How many women have osteoporosis?","volume":"7","author":"Melton","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024013019221788700_bib3","first-page":"293","article-title":"Medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis","volume":"7","author":"Hodgson","year":"2001","journal-title":"Endocr Pract"},{"key":"2024013019221788700_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/8756-3282(93)90341-7","article-title":"Hip fractures: A worldwide problem today and tomorrow","volume":"14","author":"Melton","year":"1993","journal-title":"Bone"},{"key":"2024013019221788700_bib5","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1016\/S0002-9343(05)80038-5","article-title":"The burden of osteoporosis: Cost","volume":"98","author":"Lindsay","year":"1995","journal-title":"Am J Med"},{"key":"2024013019221788700_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01626603","article-title":"Direct clinical and welfare costs of osteoporotic fractures in elderly men and women","volume":"5","author":"Randell","year":"1995","journal-title":"Osteoporos Int"},{"key":"2024013019221788700_bib7","first-page":"423","article-title":"The economic impact of geriatric hip fractures","volume":"28","author":"Youm","year":"1999","journal-title":"Am J Orthop"},{"key":"2024013019221788700_bib8","first-page":"1121","article-title":"Osteoporosis: Part II. Nonpharmacologic and pharmacologic treatment","volume":"63","author":"South-Paul","year":"2001","journal-title":"Am Fam Physician"},{"key":"2024013019221788700_bib9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/oxfordjournals.bmb.a072552","article-title":"HRT: An analysis of benefits, risks and costs","volume":"48","author":"Daly","year":"1992","journal-title":"Br Med Bull"},{"key":"2024013019221788700_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Women's Health Initiative Investigators","year":"2002","journal-title":"JAMA"},{"key":"2024013019221788700_bib11","first-page":"504","article-title":"Bisphosphonates in the treatment of osteoporosis. Principles and efficacy","volume":"151","author":"Papapoulos","year":"2000","journal-title":"Ann Med Interne (Paris)"},{"key":"2024013019221788700_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-128-4-199802150-00001","article-title":"Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group","volume":"128","author":"McClung","year":"1998","journal-title":"Ann Intern Med"},{"key":"2024013019221788700_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"2024013019221788700_bib14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/jbmr.5650081109","article-title":"A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs","volume":"8","author":"Monier-Faugere","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024013019221788700_bib15","first-page":"990","article-title":"The total administered dose of ibandronate determines its effect on bone mass and architecture in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J Rheumatol"},{"key":"2024013019221788700_bib16","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1359\/jbmr.1999.14.10.1768","article-title":"Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties","volume":"14","author":"Monier-Faugere","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024013019221788700_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S8756-3282(02)00923-7","article-title":"Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Smith","year":"2003","journal-title":"Bone"},{"issue":"Suppl 1","key":"2024013019221788700_bib18","first-page":"S15","article-title":"Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: Results from a pivotal phase III study","volume":"13","author":"Delmas","year":"2002","journal-title":"Osteoporos Int"},{"key":"2024013019221788700_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-finding study","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"key":"2024013019221788700_bib20","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","article-title":"Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis","volume":"16","author":"Riis","year":"2001","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.0301202","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/1\/11\/56475786\/5650190103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/1\/11\/56475786\/5650190103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:05:56Z","timestamp":1710342356000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/19\/1\/11-18\/7592905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.0301202","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,1,1]]},"published":{"date-parts":[[2004,1,1]]}}}